Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019)

Fulcrum Therapeutics (FULC) has reported Preferred Stock Liabilities for 2 consecutive years, with $105.2 million the latest figure, recorded in Q2 2019.

• In Q2 2019, Preferred Stock Liabilities rose 75.64% year-over-year to $105.2 million; the TTM figure through Jun 2019 stood at $105.2 million (up 75.64% YoY), while the FY2018 annual figure was $79.8 million, changed N/A from the prior year.
• Preferred Stock Liabilities was little changed at $105.2 million in Q2 2019 per FULC's latest filing, from $105.2 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $105.2 million in Q1 2019 and bottomed at $59.9 million in Q2 2018.